View by Specialty

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

Cell Therapy News

SPONSORED CONTENT
Save
SPONSORED CONTENT
November 17, 2020
1 min read
Save

FDA further delays decision on lisocabtagene maraleucel CAR-T for large B-cell lymphoma

FDA further delays decision on lisocabtagene maraleucel CAR-T for large B-cell lymphoma

The FDA for a second time delayed a decision on a biologics license application for lisocabtagene maraleucel, a chimeric antigen receptor T-cell therapy for the treatment of adults with relapsed or refractory large B-cell lymphoma.

SPONSORED CONTENT
November 16, 2020
3 min read
Save

Letetresgene autoleucel safe, active in advanced synovial sarcoma

Letetresgene autoleucel safe, active in advanced synovial sarcoma

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

SPONSORED CONTENT
November 16, 2020
3 min read
Save

Letetresgene autoleucel safe, active in advanced synovial sarcoma

Letetresgene autoleucel safe, active in advanced synovial sarcoma

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

SPONSORED CONTENT
November 15, 2020
1 min read
Save

AABB installs 2020-2021 president

David R. Green, MSA, has been installed as president of AABB for the 2020-2021 term.

SPONSORED CONTENT
November 13, 2020
2 min read
Save

Clinicians need more education on emerging cancer immunotherapies, survey shows

Clinicians need more education on emerging cancer immunotherapies, survey shows

Nearly half of oncology clinicians reported being unfamiliar with emerging immunotherapies, according to survey results presented at the virtual Society for Immunotherapy of Cancer’s Annual Meeting.

SPONSORED CONTENT
November 10, 2020
3 min read
Save

Radiation therapy safe before CAR T-cell infusion for advanced multiple myeloma

Radiation therapy safe before CAR T-cell infusion for advanced multiple myeloma

Localized radiation therapy appeared safe before treatment with chimeric antigen receptor T cells for relapsed or refractory multiple myeloma, according to study results presented at the virtual ASTRO Annual Meeting.

SPONSORED CONTENT
November 05, 2020
1 min read
Save

FDA grants orphan drug designation to natural killer cell therapy for multiple myeloma

FDA grants orphan drug designation to natural killer cell therapy for multiple myeloma

The FDA granted orphan drug designation to CellProtect, a modified natural killer cell therapy for the treatment of patients with multiple myeloma, according to the agent’s manufacturer.

SPONSORED CONTENT
October 29, 2020
2 min read
Save

FDA clears IND application for CAR-T targeting B-cell-activating factor receptor in ALL

FDA clears IND application for CAR-T targeting B-cell-activating factor receptor in ALL

The FDA cleared an investigational new drug application for PMB-101, a chimeric antigen receptor T-cell therapy, for the treatment of refractory or relapsed B-cell acute lymphoblastic leukemia.

SPONSORED CONTENT
October 29, 2020
3 min read
Save

COVID-19, manufacturing challenges limit cell and gene therapy progress, FDA official says

COVID-19, manufacturing challenges limit cell and gene therapy progress, FDA official says

Progress in the field of gene and cell therapy continues with rapid development despite the negative impact of COVID-19 on research into novel treatments, according to the director of FDA’s Center for Biologics Evaluation and Research.

SPONSORED CONTENT
October 28, 2020
5 min read
Save

Autologous vs. allogeneic CAR-T: Decisions must be made ‘carefully and deliberately’

Autologous vs. allogeneic CAR-T: Decisions must be made ‘carefully and deliberately’

Allogeneic or “off-the-shelf” chimeric antigen receptor T-cell therapies have moved into early-phase clinical testing with the hope that they will offer many advantages over autologous regimens.

View more